title: Hyperparathyroidism of Renal Disease.
abstract: Renal hyperparathyroidism (rHPT) is a common complication of chronic kidney disease characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D. Patients with rHPT experience increased rates of cardiovascular problems and bone disease. The Kidney Disease: Improving Global Outcomes guidelines recommend that screening and management of rHPT be initiated for all patients with chronic kidney disease stage 3 (estimated glomerular filtration rate, < 60 mL/min/1.73 m(2)). Since the 1990s, improving medical management with vitamin D analogs, phosphate binders, and calcimimetic drugs has expanded the treatment options for patients with rHPT, but some patients still require a parathyroidectomy to mitigate the sequelae of this challenging disease.
authors.affiliation: Surgical Resident at the University of California, Davis in Sacramento. nkyuen@ucdavis.edu.
authors.forename: Noah K
authors.initials: NK
authors.lastname: Yuen
authors.affiliation: Assistant Professor of Internal Medicine at the University of California, Davis in Sacramento. sananthakrishnan@ucdavis.edu.
authors.forename: Shubha
authors.initials: S
authors.lastname: Ananthakrishnan
authors.affiliation: Assistant Professor in the Department of Surgery at the University of California, Davis in Sacramento. mjcampb@ucdavis.edu.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Campbell
mesh_terms: D002140:California; D003657:Decision Making; D006801:Humans; D006961:Hyperparathyroidism / Q000175:diagnosis / Q000178:diet therapy / Q000188:drug therapy / Q000503:physiopathology; D007676:Kidney Failure, Chronic; D028044:Phosphate-Binding Proteins / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D028044:Phosphate-Binding Proteins; D014807:Vitamin D